We provide molecular insights into the diverse TCE strategies being employed against PCa (targeting PSMA, STEAP1, and DLL3), critically evaluate their associated clinical outcomes, and synthesize the lessons learned thus far. This evidence concerns the gene STEAP1 and posterior cortical atrophy.